Navigation Links
Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma

tatus for CTCL and PTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-474-2825.

Contact

Media:
KMorrisPR
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com
or
Gloucester Pharmaceuticals
Beverly Holley, 617-583-1362
beverly.holley@gloucesterpharma.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib Combination in Non-Small Cell Lung Cancer Presented at American Association of Cancer Research Annual Meeting
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:10/13/2008)...ave Higher Sensitivity and Specificity, than Othe...he preferred test in all phases of...- AT First Diagnostic LLC an,emerging...st kits, today,announced that a recent evaluation ...earch of the FirstVue(TM) HBSAG Test, was released...
(Date:10/13/2008)...tiple Cancer Populations Facilitates ...Oct. 13 /- Rubicon Genomics, Inc. tod...mplify DNA samples for The,Cancer Atlas Genome Pro...nd standardize total genomic,DNA from 3,000 tissue...on,GenomePlex(TM) Whole Genome Amplification techn...
(Date:10/12/2008)...in Combination with Chemotherapy, FREMONT, Calif....c., a,development-stage pharmaceutical company dis...Ai)-based therapeutics, today announced that the,j...cy of siRNA targeting,its proprietary target gene ...edition dated October 1, 2008. The paper, entitled...
(Date:10/12/2008)...t. 12 /- Boston,Scientific ...from an analysis,of nearly 7,500 patients from its...ed to confirm the performance of the TAXUS(R) Expr...in real-world practice. The,two-year pooled ARRIVE...,restenosis in patients with diabetes as effective...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Previously unseen switch regulates breast cancer response to estrogen 18812 1Previously unseen switch regulates breast cancer response to estrogen 18812 2Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 1Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 1Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 3
...ically meaningful pain relief within 5,minutes of ... June 2007 - Archimedes Pharma Ltd,("Archimedes"),...y,presented new clinical data from a Phase II stud...nasal spray aimed at providing a,fast, effective a...in. Data were presented at the 10th Congress of th...
...ating zonisamide SR as a novel component in,EMPATI... 2007 /PRNewswire-FirstCall/ -- Orexigen(TM),Thera...d on the,treatment of central nervous system disor...nced results from a Phase I trial evaluating,safet...sustained-release (SR) formulation of zonisamide. ...
Other Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
... the womb! Mothers can prevent the occurrence of c...e course of life //just by having a nutritious die...vegetables like cabbage and broccoli. A new study ...titute at Oregon State University, done with labor...
...nics were developed by scientists with a vision to... all defective genes from the gene pool. // But no...ade to order. Though it sounds absurd, ‘why should...To some parents with disabilities like deafness an...
...indicated that blood tests which were designed to ... good //as cholesterol tests , or blood pressure t... veritable risk indicator. Doctors have been mak...d which they interpreted as indicators of a heart ...
..., effectiveness and reliability of LASIK and LASEK...etween the two types of laser eye// surgery. The ...researcher, is published in the December 2006 issu...f Ophthalmology. "Although there have been many s...
Other Medicine News:Health News:Cancer Prevention Begins During Pregnancy 2Health News:Cancer Prevention Begins During Pregnancy 3Health News:Can Defective Babies Be Made To Order? 2Health News:Study Compares LASIK and LASEK Eye Surgery 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: